Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer  Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Published byPolly Weaver Modified over 5 years ago

Similar presentations

Presentation on theme: "The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer  Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,"— Presentation transcript:

1 The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer 
Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD, Tomoyuki Hishida, MD, PhD, Mitsuyo Nishimura, MD, PhD, Kanji Nagai, MD, PhD  Journal of Thoracic Oncology  Volume 6, Issue 4, Pages (April 2011) DOI: /JTO.0b013e318208e963 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Overall survival and recurrence-free proportion (RFP) curves according to smoking status in the entire cohort. A, Overall survival curves according to smoking extent. B, RFP curves according to smoking extent. C, Overall survival curves according to smoking history. D, RFP curves according to smoking history. PY, pack-years. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e318208e963) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Overall survival and recurrence-free proportion (RFP) curves according to smoking history in each stage. A, Overall survival curves of patients with stage I non-small cell lung cancer (NSCLC). B, Overall survival curves of patients with stage II NSCLC. C, Overall survival curves of patients with stage III NSCLC. D, RFP curves of patients with stage I NSCLC. E, RFP curves of patients with stage II NSCLC. F, RFP curves of patients with stage III NSCLC. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e318208e963) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Overall survival and recurrence-free proportion (RFP) curves according to smoking history in patients with stage I non-small cell lung cancer. A, Overall survival curves of adenocarcinoma patients. B, Overall survival curves of nonadenocarcinoma patients. C, RFP curves of adenocarcinoma patients. D, RFP curves of nonadenocarcinoma patients. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e318208e963) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer  Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Histopathologic Prognostic Factors in Resected Colorectal Lung Metastases  Satoshi Shiono, MD, Genichiro Ishii, MD, Kanji Nagai, MD, Junji Yoshida, MD,

Histopathologic Prognostic Factors in Resected Colorectal Lung Metastases  Satoshi Shiono, MD, Genichiro Ishii, MD, Kanji Nagai, MD, Junji Yoshida, MD,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
The impact on survival of positive intraoperative pleural lavage cytology in patients with non–small-cell lung cancer  Keiju Aokage, MD, Junji Yoshida,

The impact on survival of positive intraoperative pleural lavage cytology in patients with non–small-cell lung cancer  Keiju Aokage, MD, Junji Yoshida,
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Prognostic Impact of CD204-Positive Macrophages in Lung Squamous Cell Carcinoma: Possible Contribution of Cd204-Positive Macrophages to the Tumor-Promoting.

Prognostic Impact of CD204-Positive Macrophages in Lung Squamous Cell Carcinoma: Possible Contribution of Cd204-Positive Macrophages to the Tumor-Promoting.
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Mediastinal Nodal Involvement in Patients with Clinical Stage I Non–Small-Cell Lung Cancer: Possibility of Rational Lymph Node Dissection  Tomohiro Haruki,

Mediastinal Nodal Involvement in Patients with Clinical Stage I Non–Small-Cell Lung Cancer: Possibility of Rational Lymph Node Dissection  Tomohiro Haruki,

Similar presentations

Ads by Google